Tuesday, 4 June 2013

First BRCA Targeted Drug Shows Early Promise, BioMarin Jumping to Phase III Trials

Although the aim of the Phase I/II trial was to evaluate the maximum tolerated dose (MTD) and the secondary aim was to evaluate safety and preliminary effects of the drug, the positive clinical results are pushing the company to pursue Phase III ...
http://www.medicaldaily.com/articles/16129/20130603/brca-target-brca-mutation-biomarin-drug-breast-cancer-ovarian-cancer.htm



BY WORLD DRUG TRACKER
DR ANTHONY CRASTO

No comments:

Post a Comment